BIOATLA, INC. Operating Income
BIOATLA, INC. (BCAB) reported Operating Income of $227.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- BIOATLA, INC. operating income (loss) for the quarter ending 2026-06-30 was $227.00K.
- BIOATLA, INC. operating income (loss) for the quarter ending 2026-03-31 was -$9.31M.
- BIOATLA, INC. operating income (loss) for the quarter ending 2025-12-31 was -$9.26M.
- BIOATLA, INC. operating income (loss) for the quarter ending 2025-09-30 was -$13.79M.
- BIOATLA, INC. operating income (loss) for fiscal 2025 was -$59.30M.
- BIOATLA, INC. operating income (loss) for fiscal 2024 was -$73.94M.
- BIOATLA, INC. operating income (loss) for fiscal 2023 was -$129.69M.
- BIOATLA, INC. operating income (loss) for fiscal 2022 was -$108.14M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $227.00K 10-Q · filed 2026-08-13 | -$9.08M 10-Q · filed 2026-08-13 | -$18.34M derived: sum of 3 quarters · filed 2026-08-13 | -$32.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$9.31M 10-Q · filed 2026-05-15 | -$18.56M derived: sum of 2 quarters · filed 2026-05-15 | -$32.35M derived: sum of 3 quarters · filed 2026-05-15 | -$51.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$9.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$23.04M derived: sum of 2 quarters · filed 2026-03-31 | -$41.69M derived: sum of 3 quarters · filed 2026-08-13 | -$59.30M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$13.79M 10-Q · filed 2025-11-13 | -$32.44M derived: sum of 2 quarters · filed 2026-08-13 | -$50.05M 10-Q · filed 2025-11-13 | -$66.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$18.65M 10-Q · filed 2026-08-13 | -$36.26M 10-Q · filed 2026-08-13 | -$52.51M derived: sum of 3 quarters · filed 2026-08-13 | -$63.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$17.61M 10-Q · filed 2026-05-15 | -$33.86M derived: sum of 2 quarters · filed 2026-05-15 | -$45.13M derived: sum of 3 quarters · filed 2026-05-15 | -$67.10M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$16.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$27.51M derived: sum of 2 quarters · filed 2026-03-31 | -$49.49M derived: sum of 3 quarters · filed 2026-03-31 | -$73.94M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$11.27M 10-Q · filed 2025-11-13 | -$33.24M derived: sum of 2 quarters · filed 2025-11-13 | -$57.70M 10-Q · filed 2025-11-13 | -$86.23M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$21.97M 10-Q · filed 2025-08-07 | -$46.43M 10-Q · filed 2025-08-07 | -$74.97M derived: sum of 3 quarters · filed 2025-08-07 | -$109.98M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$24.46M 10-Q · filed 2025-05-06 | -$52.99M derived: sum of 2 quarters · filed 2025-05-06 | -$88.01M derived: sum of 3 quarters · filed 2025-05-06 | -$125.21M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$28.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$63.56M derived: sum of 2 quarters · filed 2025-03-28 | -$100.76M derived: sum of 3 quarters · filed 2025-03-28 | -$129.69M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$35.02M 10-Q · filed 2024-11-07 | -$72.22M derived: sum of 2 quarters · filed 2024-11-07 | -$101.15M 10-Q · filed 2024-11-07 | -$129.71M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$37.20M 10-Q · filed 2024-08-08 | -$66.13M 10-Q · filed 2024-08-08 | -$94.69M derived: sum of 3 quarters · filed 2024-08-08 | -$120.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$28.93M 10-Q · filed 2024-05-14 | -$57.49M derived: sum of 2 quarters · filed 2024-05-14 | -$83.67M derived: sum of 3 quarters · filed 2024-05-14 | -$112.72M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$28.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$54.74M derived: sum of 2 quarters · filed 2024-03-26 | -$83.79M derived: sum of 3 quarters · filed 2024-03-26 | -$108.14M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$26.18M 10-Q · filed 2023-11-07 | -$55.23M derived: sum of 2 quarters · filed 2023-11-07 | -$79.58M 10-Q · filed 2023-11-07 | -$103.07M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$29.05M 10-Q · filed 2023-08-01 | -$53.40M 10-Q · filed 2023-08-01 | -$76.89M derived: sum of 3 quarters · filed 2023-08-01 | -$100.58M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$24.35M 10-Q · filed 2023-05-11 | -$47.83M derived: sum of 2 quarters · filed 2023-05-11 | -$71.53M derived: sum of 3 quarters · filed 2023-05-11 | -$101.99M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$23.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$47.18M derived: sum of 2 quarters · filed 2023-03-23 | -$77.64M derived: sum of 3 quarters · filed 2023-03-23 | -$96.44M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$23.70M 10-Q · filed 2022-11-04 | -$54.16M derived: sum of 2 quarters · filed 2022-11-04 | -$72.95M 10-Q · filed 2022-11-04 | -$89.41M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | -$30.46M 10-Q · filed 2022-08-09 | -$49.26M 10-Q · filed 2022-08-09 | -$65.71M derived: sum of 3 quarters · filed 2022-08-09 | -$73.73M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$18.80M 10-Q · filed 2022-05-05 | -$35.25M derived: sum of 2 quarters · filed 2022-05-05 | -$43.27M derived: sum of 3 quarters · filed 2022-05-05 | -$47.79M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$24.47M derived: sum of 2 quarters · filed 2022-02-28 | -$28.99M derived: sum of 3 quarters · filed 2022-02-28 | -$30.10M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$8.02M 10-Q · filed 2021-11-15 | -$12.54M derived: sum of 2 quarters · filed 2021-11-15 | -$13.64M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$4.52M 10-Q · filed 2021-08-13 | -$5.63M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$1.11M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$28.27M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |